bioihbjkbjnl/mcl2 huggingface dataset:
Evaluation of Two Hand Hygiene Products in ICUs
Condition: Hand Hygiene Effectiveness
Intervention: hand antiseptic with CHG and alcohol; Alcohol hand sanitizer foam
Intervention description: HCWs will be randomized to use one product on one day and the other product on another day at least 3 days apart. Each product will be applied using 1 pump from its dispenser and rubbed over the hands until dry. Gloves will be worn while the HCW is in the patient room. Upon exit from the room, HCW will washoout with that same product. One imprint will be made of the non-dominant hand onto media containing neutralizers. That hand will be gloved with a white cotton glove. The HCW will work in the common areas with timing recorded. Upon leaving the common area, the dominant ungloved hand will be imprinted onto a fresh media plate containing neutralizers.; Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day
Intervention MeSH terms: Ethanol; Anti-Infective Agents, Local; Hand Sanitizers
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Enrollment: 51.0
Sex: All
Minimum age: 18 Years
Maximum age: 70 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: antimicrobial; efficacy; hand; hygiene; bacteria

Summary:

      This study will evaluate the immediate antimicrobial efficacy and persistence of two hand
      hygiene products on ICU Health Care Worker's skin flora by measuring bacterial organisms on
      hands using the hand print method. It is hypothesized that the product containing
      Chlorhexidine gluconate will provide more persistence than the alcohol product, resulting in
      less bacterial growth on the hand print plates. In addition, environmental monitoring for
      cleanliness will be captured from high touch surfaces in ICU patient rooms and common areas
      using Rodac plates and adenosine triphosphate tests.
    

Eligibility criteria:

        Inclusion Criteria:

          -  HCW willing to participate in the study

          -  HCW willing to use non-Triclosan soap when soap is necessary throughout the study

          -  HCW who will don gloves prior to ICU patient room entry

        Exclusion Criteria:

          -  Use of any CHG -containing products ( liquid hand soap, Sage wipes) on the ICU 72
             hours prior to study initiation and throughout study

          -  HCW with patient bandage or other dressing on palm(s)

          -  Known sensitivity or allergy to CHG or alcohols in hand hygiene products

          -  Known sensitivity or allergy to the following components: Lecithin, Polysorbate
             80,Trypticase Soy Agar, sodium bisulfate, sodium thioglycollate, sodium thiosulfate

          -  History of skin allergies
Platelet Inhibition in Patients With Systolic Heart Failure
Condition: Systolic Heart Failure
MeSH terms: Heart Failure; Heart Failure, Systolic; Systolic Murmurs
Intervention: Prasugrel 10 mg daily x 2 weeks; Clopidogrel 75 mg daily x 2 weeks
Intervention MeSH terms: Clopidogrel; Prasugrel Hydrochloride
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 30.0
Sex: All
Minimum age: 19 Years
Maximum age: 75 Years
Healthy volunteers: No
Keywords: Heart failure; Antiplatelet therapy; Platelet aggregation; Clopidogrel; Prasugrel

Summary:

      The investigators aim to determine if patients with systolic heart failure treated with
      prasugrel achieve greater platelet inhibition compared to those treated with clopidogrel.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Patients 19 to 74 years of age.

          -  Patients with a left ventricular ejection fraction <35% by echocardiogram, SPECT
             myocardial perfusion study, cardiac MRI, cardiac computerized tomographic angiogram or
             invasive left ventricular angiogram within the last 6 months.

          -  Patients with NYHA Class III-IV heart failure at the time of enrollment.

        Exclusion Criteria:

          -  Recent hospitalization within 30 days

          -  Patients expected to undergo major surgery or PCI in the next 30 days

          -  Patients taking clopidogrel, prasugrel, ticagrelor, ticlopidine, or cilostazol

          -  Patients listed for heart transplantation or having left ventricular assist device
             placement

          -  Patients with known allergy to either medication

          -  Patients with prior history of stroke or transient ischemic attack

          -  Patients with known intracranial neoplasm, aneurysm, or arteriovenous malformation

          -  Patients with a history of bleeding requiring hospitalization for treatment

          -  Patients taking oral anticoagulants

          -  Patients with body weight <60 kg

          -  Women who are pregnant or breastfeeding

          -  Patients with hemoglobin <10 mg/dl or platelet count <100,000/ul at baseline

          -  Patients with known clotting or platelet disorders

          -  Patients with a baseline INR > 1.4

          -  Patients with liver function tests (AST or ALT) > 2 times normal

          -  Patients with a suspected change in their use of aspirin during the study (starting,
             stopping, or changing dose of aspirin)

          -  Patients unwilling to consent to CYP2C19 genetic testing.
A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease
Condition: COPD
MeSH terms: Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive
Intervention: Fluticasone propionate; Placebo
Intervention MeSH terms: Fluticasone; Xhance
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Enrollment: 18.0
Sex: All
Minimum age: 50 Years
Maximum age: 90 Years
Healthy volunteers: No

Summary:

      Chronic Obstructive Pulmonary Disease (COPD) is a major worldwide problem.Steroids inhalers
      are now an established treatment for COPD. Inhaled steroids can have a number of bad effects
      including suppression of the adrenal glands because of absorption. A previous study in
      patients with COPD.

      C-reactive Protein (CRP) is a peptide produced in the liver in response to inflammation.
      Elevated circulating levels of CRP are associated with heart conditions. High levels of CRP
      have also been found in patients with COPD. In some studies, steroid inhalers have reduced
      CRP levels, and that of other inflammatory mediators, in patients with COPD. It is unknown
      whether this reflects a reduction in lung inflammation or an effect of systemically absorbed
      corticosteroid.

      It is proposed to investigate the link between inhaled corticosteroid and serum CRP, lung
      inflammation (measured by exhaled nitric oxide) and systemic absorption of steroids.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Current or ex-smokers

          -  Aged over 50years

          -  FEV1/FVC ratio <0.7

          -  FEV1<80% predicted

          -  Improvement in FEV1 following short acting beta-agonist not greater than 15% and
             200ml.

        Exclusion Criteria:

          -  Diagnosis of asthma, bronchiectasis or ABPA

          -  Inability to perform study procedures or give informed consent

          -  Known sensitivity to trial medications
A Novel Analgesia Technique for ACL Reconstruction
Condition: Anterior Cruciate Ligament Injury
MeSH terms: Anterior Cruciate Ligament Injuries
Intervention: Bupivacaine; Ultrasound; Dexamethasone
Intervention description: Bupivacaine will help treat pain and sensation after ACL repair; Ultrasound will guide anesthesiologist in performing the different nerve blocks; Dexamethasone will be used to prolong block duration
Intervention MeSH terms: Dexamethasone; Dexamethasone acetate; Bupivacaine; BB 1101
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Enrollment: 78.0
Sex: All
Minimum age: 13 Years
Maximum age: 80 Years
Healthy volunteers: No

Summary:

      A comparison of two anesthetic techniques-- the Adductor Canal Block (ACB) and the Adductor
      Canal Block with Infiltration of the interspace between the popliteal artery and the capsule
      of the posterior knee (ACB/IPACK)-- in patients undergoing bone-tendon-bone (BTB) anterior
      cruciate ligament (ACL) reconstruction.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Patients undergoing BTB ACL reconstruction with participating surgeon

          -  Age 13 or greater

          -  Planned use of regional anesthesia

          -  Ability to follow study protocol

          -  English speaking (secondary outcomes include questionnaires validated in English only)

        Exclusion Criteria:

          -  Hepatic or renal insufficiency

          -  Younger than 13 years old

          -  Patients undergoing general anesthesia

          -  Allergy or intolerance to one of the study medications

          -  BMI > 40

          -  Diabetes

          -  American Society of Anesthesiology (ASA) score IV

          -  Chronic gabapentin/pregabalin use (regular use for longer than 3 months)

          -  Chronic opioid use (taking opioids for longer than 3 months, or daily morphine
             equivalent of >5mg/day for one month)

          -  Non-English speaking
Neuroimaging of Anesthetic Modulation of Human Consciousness
Condition: Healthy
Intervention: Propofol
Intervention description: Propofol administration
Intervention MeSH terms: Propofol
Phase: Phase 4
Study type: Interventional
Primary purpose: Basic Science
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 30.0
Sex: All
Minimum age: 18 Years
Maximum age: 40 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      This study's purpose is to see if mental functions take place during different levels of
      anesthesia, using a commonly used drug (Propofol). fMRI (functional Magnetic Resonance
      Imaging, or "brain imaging") shows areas in the brain involved in thinking at different
      depths of anesthesia.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Must have a body mass index (BMI) less than 30.

          2. Must be right handed

          3. Must be English speaking

          4. Must be capable of giving written informed consent.

          5. Must have history of playing tennis (or any type of racquet sport) at least 30 times
             over lifetime.

        Exclusion Criteria:

          1. History of obstructive sleep apnea;

          2. History of a difficult airway with a previous anesthetic;

          3. History of neurological disorders;

          4. Hypertension or other cardiovascular abnormalities;

          5. Pulmonary hypertension or other pulmonary abnormalities;

          6. Gastroesophageal reflux disease (GERD) or heartburn;

          7. History of significant head injury with loss of consciousness;

          8. Learning disability or other developmental disorder;

          9. Allergic reactions to eggs;

         10. Pregnant or nursing mothers;

         11. Contraindications to neuroimaging methods;

         12. Inability or unwilling to fast, or withhold food and liquid intake, for 8 hours prior
             to your scheduled study visit.

         13. Unwilling to abstain from alcohol use for 24 hours prior to your scheduled study
             visit.

         14. History of drug use, or have a positive drug screen.

         15. Tattoos on the head or neck region - all other tattoos are subject to determination by
             investigators.

         16. Any impairment, activity or situation that in the judgment of the study coordinator or
             Principal Investigators would prevent satisfactory completion of the study protocol.
Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery
Condition: Chronic Sinusitis; Nasal Obstruction; Turbinate; Hypertrophy Mucous Membrane; Deviated Nasal Septum - Congenital; Deviated Nasal Septum Acquired
MeSH terms: Sinusitis; Nasal Obstruction; Hypertrophy; Postoperative Hemorrhage
Intervention: Tranexamic Acid 1,000 Mg/10 mL (100 Mg/mL) INTRAVEN VIAL (ML)
Intervention description: Medication administered 15 minutes prior to end of surgery.
Intervention MeSH terms: Tranexamic Acid
Phase: Phase 4
Study type: Interventional
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Enrollment: 40.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      The purpose of the research is to assess the effectiveness of a dose of intravenous
      tranexamic acid (TXA) given intraoperatively to reduce postoperative bleeding after
      endoscopic sinus or nasal surgery (e.g. septoplasty, endoscopic sinus surgery, turbinate
      surgery). This medication has been shown to decrease blood loss during this type of surgery,
      but the implications for bleeding following surgery are unclear. Any impact on postoperative
      bleeding will be assessed over the first 7 days following surgery leading up to the first
      scheduled postoperative clinic visit. Patients will keep a standardized daily diary of their
      bleeding experience by indicating on a 0-10 visual analog scale (VAS) their impression of
      their bleeding.

      The primary outcome is the patient-reported visual analog scale (VAS) bleeding score on each
      day after surgery. The secondary outcomes include the the frequency with which the
      otolaryngology resident service is requested to evaluate patients in the recovery unit for
      postoperative bleeding concerns and the frequency of interventions such as application of
      hemostatic materials, packing, cautery, and/or return to the operating room.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Scheduled to undergo elective sinus or nasal surgery (e.g. septoplasty, inferior
             turbinate reduction, endoscopic sinus surgery)

          -  Age 18 or greater

          -  English-speaking

          -  Able to provide consent

        Exclusion Criteria:

          -  Minors (age<18)

          -  Pregnant or may become pregnant by time of surgery

          -  Prisoners

          -  Non-English speaking

          -  Foreign citizens

          -  Unable to provide consent

          -  Known pro-thrombotic coagulation disorders

          -  Active intranasal drug use (e.g. cocaine)

          -  Surgery is for a sinonasal tumor or other sinus pathology not described in inclusion
             criteria

          -  Enrollment is in conflict with existing study participation
Angiotensin II Blockade for Chronic Allograft Nephropathy
Condition: Kidney Disease; Proteinuria
MeSH terms: Kidney Diseases; Proteinuria
Intervention: Losartan 100mg; Placebo
Intervention description: To be started within three months of transplant and continued for five years.; No treatment with continued follow-up for five years.
Intervention MeSH terms: Losartan
Phase: Phase 4
Study type: Interventional
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Enrollment: 153.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: chronic allograft nephropathy; post transplant proteinuria

Summary:

      Chronic allograft nephropathy continues to be a major cause of kidney transplant loss and
      return to dialysis. Treatment options are limited and the course of the disease tends to be
      progressive. This trial is designed to prevent a major mediator of this process, namely the
      expansion of the cortical interstitial compartment of the kidney where most of the scarring
      occurs. The drug being studied, Losartan, has proven efficacious in a number of kidney
      diseases.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Age > 18 years.

          -  Recipients of a first or a second renal transplant alone or in combination with a
             pancreas transplantation.

          -  Informed consent

          -  Adequate baseline biopsy; at least 10 cortical projection fields.

        Exclusion Criteria:

          -  Age < 18 years.

          -  Serum creatinine 2.5mg/dL.

          -  Persistent hyperkalemia; potassium > 5.4 mEq/L.

          -  Known hypersensitivity to losartan or iodine allergy.

          -  Documented renal artery stenosis by duplex ultrasonography.

          -  Recipients of grafts from an HLA-identical sibling.

          -  Recipients whose primary renal disease is primary hyperoxaluria,dense-deposit disease,
             focal segmental glomerulosclerosis or hemolytic uremic syndrome.

          -  Women of childbearing age who wish to become pregnant and/or are unwilling to use
             contraceptive measures or who are pregnant.

          -  Recipients requiring ACE inhibitors or AII blockers for a cardiovascular indication
             (e.g. systolic dysfunction).

          -  Recipients who are > 55 years old and had a history of cardiovascular disease
             (coronary artery disease, stroke or peripheral vascular disease).
Fluoxetine vs Aripiprazole Comparative Trial (FACT)
Condition: Attenuated Psychosis Syndrome
MeSH terms: Psychotic Disorders; Mental Disorders
Intervention: Aripiprazole; Fluoxetine
Intervention description: see arm description; see arm description
Intervention MeSH terms: Aripiprazole; Fluoxetine
Phase: Phase 4
Study type: Interventional
Primary purpose: Other
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 9.0
Sex: All
Minimum age: 12 Years
Maximum age: 25 Years
Healthy volunteers: No

Summary:

      We are conducting a randomized, 24-week, double-blind study, comparing fluoxetine with
      aripiprazole in 48 patients with attenuated positive symptoms at a level of at least moderate
      severity.
    

Eligibility criteria:

        Inclusion Criteria:

          -  consent obtained from patients and their parents (assent for patients under 18);

          -  age 12-25 years (inclusive);

          -  English-speaking;

          -  at least one positive (Scale A) SOPS score of 3-5, i.e., moderate, moderately severe
             or severe.

        Exclusion Criteria:

          -  lifetime diagnosis of an Axis I psychotic disorder, including: schizophreniform
             disorder, schizophrenia, schizoaffective disorder, bipolar disorder, or major
             depression with psychotic features;

          -  current psychosis (any positive symptom SOPS score of 6, i.e., extreme);

          -  current diagnosis of Major Depressive Disorder, single episode or recurrent, severe
             without psychotic features;

          -  current stimulant treatment;

          -  history of neurological, neuroendocrine or other medical condition known to affect the
             brain;

          -  any significant medical condition that contra-indicates treatment with either
             aripiprazole or fluoxetine;

          -  past or current substance dependence; sunstance abuse within the last 4 weeks;

          -  IQ < 70.
Metformin in Longevity Study (MILES).
Condition: Aging
Intervention: Metformin; Placebo
Intervention description: To determine if treatment with metformin (1700 mg/day) will restore the gene expression profile of older, glucose intolerant adults to that of young healthy subjects.; there is no other name we used for the placebo
Intervention MeSH terms: Metformin
Phase: Phase 4
Study type: Interventional
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Enrollment: 16.0
Sex: All
Minimum age: 60 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: aging; metformin; prediabetes

Summary:

      Metformin, an FDA approved first-line drug for the treatment of type 2 diabetes, has known
      beneficial effects on glucose metabolism. Evidence from animal models and in vitro studies
      suggest that in addition to its effects on glucose metabolism, metformin may influence
      metabolic and cellular processes associated with the development of age-related conditions,
      such as inflammation, oxidative damage, diminished autophagy, cell senescence and apoptosis.
      As such, metformin is of particular interest in clinical translational research in aging
      since it may influence fundamental aging factors that underlie multiple age-related
      conditions. The investigators therefore propose a pilot study to examine the effect of
      metformin treatment on the biology of aging in humans. Namely, whether treatment with
      metformin will restore the gene expression profile of older adults with impaired glucose
      tolerance (IGT) to that of young healthy subjects.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Men and women;

          2. age >60 years with IGT based on 75g OGTT (fasting plasma glucose < 126 mg/dl, 2-hr
             glucose between 140 - 199 mg/dl);

          3. this definition of IGT will include individuals with combined impaired fasting glucose
             (IFG) and IGT.

        The investigators chose these inclusion criteria in order to study subjects who have
        evidence of impaired glucose regulation, but are not yet diabetic.

        Exclusion Criteria:

          1. Serious chronic or acute illness: cancer, clinically significant congestive heart
             failure, COPD, inflammatory conditions, serum creatinine > 1.4 mg/dl (female) or > 1.5
             mg/dl (male), active liver disease, history of metabolic acidosis, poorly controlled
             hypertension, epilepsy, recent (within 3 months) CVD event (MI, PTCA, CABG, stroke);
             history of bariatric or other gastric surgery, cigarette smoking, binge alcohol use
             (>7 drinks in 24 hrs).

          2. Treatment with drugs known to influence glucose metabolism (other diabetes
             medications, systemic glucocorticoids, pharmacologic doses of niacin)

          3. Hypersensitivity to metformin or any component of the formulation